Jove
Visualize
Contact Us

Related Experiment Videos

Regulatory issues in aging pharmacology.

Franz F Hefti1, Roxanne Bales

  • 1Rinat Neuroscience Corporation, South San Francisco, California 94080, USA. hefti@rinatneuro.com

Aging Cell
|January 31, 2006
PubMed
Summary

Future drugs may extend lifespan by targeting aging mechanisms, not just diseases. Developing these requires new strategies for safety, long-term studies, and regulatory approval, potentially using biomarkers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.

Pain reports·2018
Same author

(18)F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons.

PET clinics·2016
Same author

Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2012
Same author

Requirements for a lead compound to become a clinical candidate.

BMC neuroscience·2008
Same author

Novel class of pain drugs based on antagonism of NGF.

Trends in pharmacological sciences·2005
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Gerontology and drug development.
  • Molecular mechanisms of aging.
  • Regulatory science for longevity interventions.

Background:

  • Current drug development focuses on treating diseases to extend lifespan.
  • Aging research reveals potential to target aging pathways directly for lifespan extension.
  • Existing regulatory frameworks are not designed for anti-aging therapeutics.

Purpose of the Study:

  • To explore strategies for developing and regulating future drugs that target aging mechanisms.
  • To address the challenges of high safety requirements and long study durations for longevity drugs.
  • To propose pathways for the development and approval of aging-modulating therapeutics.

Main Methods:

  • Review of current drug development and regulatory paradigms.
  • Analysis of challenges posed by targeting aging in healthy populations.
  • Proposal of two potential pathways for drug development and regulatory approval.

Main Results:

  • Novel drugs targeting aging mechanisms require distinct development and regulatory strategies.
  • High safety standards and extended clinical trials are necessary for longevity interventions.
  • Biomarkers of aging could serve as surrogate endpoints in clinical studies.

Conclusions:

  • Developing drugs that regulate aging requires new approaches beyond disease treatment.
  • Public funding and biomarker-based trials are potential pathways for aging intervention research.
  • Regulatory agencies need to establish guidance for longevity-enhancing drug development.

Related Experiment Videos